671 related articles for article (PubMed ID: 17391756)
1. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
2. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
3. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Medina J; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Rios MB; Hayes K; Cortes J
Cancer; 2003 Nov; 98(9):1905-11. PubMed ID: 14584073
[TBL] [Abstract][Full Text] [Related]
4. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
Espinet B; Oliveira AC; Boqué C; Domingo A; Alonso E; Solé F
Haematologica; 2005 Apr; 90(4):556-8. PubMed ID: 15820956
[TBL] [Abstract][Full Text] [Related]
5. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.
Mohamed AN; Pemberton P; Zonder J; Schiffer CA
Clin Cancer Res; 2003 Apr; 9(4):1333-7. PubMed ID: 12684401
[TBL] [Abstract][Full Text] [Related]
6. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
Fugazza G; Miglino M; Bruzzone R; Quintino S; Gatti AM; Grasso R; Gobbi M; Frassoni F; Sessarego M
J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
10. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
Salesi N; Bossone G; Della Longa G; Di Cocco B
Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
Kolb EA; Pan Q; Ladanyi M; Steinherz PG
Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
[TBL] [Abstract][Full Text] [Related]
12. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
[TBL] [Abstract][Full Text] [Related]
14. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
15. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.
Lin Y; Bruyère H; Horsman DE; Pantzar T; Barnett MJ; Hogge DE; Nevill TJ; Nantel SH; Sutherland HJ; Toze CL; Shepherd JD; Lavoie JC; Song KW; Smith CA; Forrest DL
Cancer Genet Cytogenet; 2006 Oct; 170(1):16-23. PubMed ID: 16965950
[TBL] [Abstract][Full Text] [Related]
16. Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Campione E; Diluvio L; Paternò EJ; Di Marcantonio D; Francesconi A; Terrinoni A; Orlandi A; Chimenti S
Clin Ther; 2009 Nov; 31(11):2565-9. PubMed ID: 20110001
[TBL] [Abstract][Full Text] [Related]
17. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
18. Trisomy 6 in a CML patient receiving imatinib mesylate therapy.
Zámecníkova A; Al Bahar S; Ramesh P
Leuk Res; 2008 Sep; 32(9):1454-7. PubMed ID: 18294688
[TBL] [Abstract][Full Text] [Related]
19. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
Terre C; Eclache V; Rousselot P; Imbert M; Charrin C; Gervais C; Mozziconacci MJ; Maarek O; Mossafa H; Auger N; Dastugue N; Talmant P; Van den Akker J; Leonard C; N'Guyen Khac F; Mugneret F; Viguié F; Lafage-Pochitaloff M; Bastie JN; Roux GL; Nicolini F; Maloisel F; Vey N; Laurent G; Recher C; Vigier M; Yacouben Y; Giraudier S; Vernant JP; Salles B; Roussi J; Castaigne S; Leymarie V; Flandrin G; Lessard M;
Leukemia; 2004 Aug; 18(8):1340-6. PubMed ID: 15190256
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease].
Bulum J; Labar B; Mikulić M; Bogdanić V; Sertić D; Nemet D; Krecak-Gverić V; Kovacević J; Serventi-Seiwerth R; Mrsić-Davidović S; Zadro R; Boban D
Lijec Vjesn; 2003; 125(7-8):176-9. PubMed ID: 14692090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
